Akero Therapeutics Inc buy UBS Group AG
Start price
05.03.24
/
50%
€26.60
Target price
05.03.25
€38.62
Performance (%)
-26.64%
Price
22.04.24
€19.52
Summary
This prediction is currently active. The prediction for Akero Therapeutics Inc disappoints with a performance of -26.64%. This prediction currently runs until 05.03.25. The prediction end date can be changed by UBS_Group_AG at any time. UBS_Group_AG has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Akero Therapeutics Inc | -4.197% | -4.197% |
| iShares Core DAX® | 2.594% | -1.158% |
| iShares Nasdaq 100 | 3.553% | -1.727% |
| iShares Nikkei 225® | 0.687% | -8.354% |
| iShares S&P 500 | 2.209% | -0.942% |
Comments by UBS_Group_AG for this prediction
In the thread Akero Therapeutics Inc diskutieren
Akero Therapeutics, Inc. (NASDAQ: AKRO) had its price target raised by analysts at UBS Group AG from $39.00 to $42.00. They now have a "buy" rating on the stock.
Ratings data for AKRO provided by MarketBeat
Stopped prediction by UBS_Group_AG for Akero Therapeutics Inc
Akero Therapeutics Inc
Start price
Target price
Perf. (%)
€14.00
12.10.23
12.10.23
€37.01
12.10.24
12.10.24
39.39%
22.04.24
22.04.24
Akero Therapeutics Inc
Start price
Target price
Perf. (%)
€46.20
28.08.23
28.08.23
€76.75
28.08.24
28.08.24
-57.76%
22.04.24
22.04.24